• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提高溶瘤病毒治疗癌症的疗效:靶向巨噬细胞。

Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.

机构信息

State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, China.

Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.

出版信息

J Transl Med. 2023 Nov 22;21(1):842. doi: 10.1186/s12967-023-04709-z.

DOI:10.1186/s12967-023-04709-z
PMID:37993941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10666393/
Abstract

Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. However, excessive antiviral immune responses also restrict the spread of OVs in vivo and the infection of tumor cells. Macrophages are functionally diverse innate immune cells that phagocytose tumor cells and present antigens to activate the immune response, while also limiting the delivery of OVs to tumors. Studies have shown that the functional propensity of macrophages between OVs and tumor cells affects the overall therapeutic effect of oncolytic virotherapy. How to effectively avoid the restrictive effect of macrophages on OVs and reshape the function of tumor-associated macrophages in oncolytic virotherapy is an important challenge we are now facing. Here, we review and summarize the complex dual role of macrophages in oncolytic virotherapy, highlighting how the functional characteristics of macrophage plasticity can be utilized to cooperate with OVs to enhance anti-tumor effects, as well as highlighting the importance of designing and optimizing delivery modalities for OVs in the future.

摘要

溶瘤病毒(OVs)在癌症治疗中处于快速发展阶段,直接肿瘤裂解和全面宿主免疫反应的激活是癌症免疫治疗不可替代的优势。然而,过度的抗病毒免疫反应也限制了 OVs 在体内的传播和肿瘤细胞的感染。巨噬细胞是功能多样的先天免疫细胞,它们吞噬肿瘤细胞并呈递抗原以激活免疫反应,同时也限制了 OVs 向肿瘤的递送。研究表明,OVs 和肿瘤细胞之间巨噬细胞的功能倾向影响溶瘤病毒治疗的整体治疗效果。如何有效避免巨噬细胞对 OVs 的限制作用,并重塑溶瘤病毒治疗中肿瘤相关巨噬细胞的功能,是我们现在面临的一个重要挑战。在这里,我们回顾和总结了巨噬细胞在溶瘤病毒治疗中的复杂双重作用,强调了如何利用巨噬细胞可塑性的功能特征与 OVs 合作增强抗肿瘤效果,并强调了未来设计和优化 OVs 传递方式的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/76a85a00dd30/12967_2023_4709_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/c61961041ec9/12967_2023_4709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/e0e0256777bf/12967_2023_4709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/4dfe37dbd30f/12967_2023_4709_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/76a85a00dd30/12967_2023_4709_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/c61961041ec9/12967_2023_4709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/e0e0256777bf/12967_2023_4709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/4dfe37dbd30f/12967_2023_4709_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f88/10666393/76a85a00dd30/12967_2023_4709_Fig4_HTML.jpg

相似文献

1
Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.提高溶瘤病毒治疗癌症的疗效:靶向巨噬细胞。
J Transl Med. 2023 Nov 22;21(1):842. doi: 10.1186/s12967-023-04709-z.
2
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.溶瘤免疫病毒治疗:病毒与免疫系统在癌症治疗中的长期相互作用。
Pharmacol Ther. 2022 Aug;236:108103. doi: 10.1016/j.pharmthera.2021.108103. Epub 2021 Dec 23.
3
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.溶瘤病毒治疗作为一种有前途的癌症免疫疗法:溶瘤病毒耐药的机制。
Future Oncol. 2022 Jan;18(2):245-259. doi: 10.2217/fon-2021-0802. Epub 2021 Nov 25.
4
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.溶瘤病毒治疗:癌症免疫治疗的新范例。
Int J Mol Sci. 2024 Jan 18;25(2):1180. doi: 10.3390/ijms25021180.
5
The Multifaceted Role of Macrophages in Oncolytic Virotherapy.巨噬细胞在溶瘤病毒治疗中的多方面作用。
Viruses. 2021 Aug 9;13(8):1570. doi: 10.3390/v13081570.
6
A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.探索溶瘤病毒与癌症免疫疗法融合:癌症治疗领域的创新策略。
Biochim Biophys Acta Rev Cancer. 2024 Jul;1879(4):189110. doi: 10.1016/j.bbcan.2024.189110. Epub 2024 May 14.
7
Oncolytic Viruses and Cancer Immunotherapy.溶瘤病毒与癌症免疫疗法
Curr Oncol Rep. 2023 Jan;25(1):19-28. doi: 10.1007/s11912-022-01341-w. Epub 2022 Nov 28.
8
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.溶瘤病毒治疗已发展为肿瘤免疫治疗的第四代。
J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8.
9
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.免疫病毒疗法:抗体药物与溶瘤病毒联合治疗的作用。
Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022.
10
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.溶瘤病毒治疗与免疫系统:抗癌的双刃剑。
Front Immunol. 2018 Apr 26;9:866. doi: 10.3389/fimmu.2018.00866. eCollection 2018.

引用本文的文献

1
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.病毒战:释放工程化溶瘤病毒以智取癌症防御。
Front Immunol. 2025 Aug 25;16:1618751. doi: 10.3389/fimmu.2025.1618751. eCollection 2025.
2
Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).溶瘤病毒疗法的耐药性:多维机制与治疗突破(综述)
Int J Mol Med. 2025 Nov;56(5). doi: 10.3892/ijmm.2025.5612. Epub 2025 Aug 24.
3
Immunological Impact of Oncolytic Adenoviruses On Cancer Therapy: Clinical Insights.

本文引用的文献

1
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.OX40L 武装溶瘤病毒增强 T 细胞反应并重塑胰腺癌治疗的肿瘤微环境。
Theranostics. 2023 Jul 9;13(12):4016-4029. doi: 10.7150/thno.83495. eCollection 2023.
2
Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma.经工程改造以强制胆固醇外排的溶瘤病毒可恢复胶质母细胞瘤中肿瘤相关巨噬细胞的吞噬作用和抗肿瘤免疫。
Nat Commun. 2023 Jul 20;14(1):4367. doi: 10.1038/s41467-023-39683-z.
3
Metabolic programming and immune suppression in the tumor microenvironment.
溶瘤腺病毒对癌症治疗的免疫影响:临床见解
Eur J Immunol. 2025 Jul;55(7):e70024. doi: 10.1002/eji.70024.
4
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
5
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.肝细胞癌的免疫治疗与肝移植:当前及未来挑战
World J Transplant. 2025 Jun 18;15(2):98509. doi: 10.5500/wjt.v15.i2.98509.
6
Advancing ORFV-Based Therapeutics to the Clinical Stage.将基于羊口疮病毒的疗法推进到临床阶段。
Rev Med Virol. 2025 May;35(3):e70038. doi: 10.1002/rmv.70038.
7
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.用于癌症免疫治疗的细菌介导的肿瘤相关巨噬细胞原位工程
Cancers (Basel). 2025 Feb 20;17(5):723. doi: 10.3390/cancers17050723.
8
Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.揭示潜力:溶瘤病毒对胶质母细胞瘤神经炎症调节的机制
Explor Target Antitumor Ther. 2025 Feb 24;6:1002294. doi: 10.37349/etat.2025.1002294. eCollection 2025.
9
Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.卵巢癌中的溶瘤病毒:我们目前的进展如何?一篇叙述性综述。
Pathogens. 2025 Feb 3;14(2):140. doi: 10.3390/pathogens14020140.
10
Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development.了解单纯疱疹病毒溶瘤株(oHSV)与宿主免疫系统之间的相互作用:对治疗性溶瘤病毒开发的启示。
Mol Ther. 2025 Apr 2;33(4):1327-1343. doi: 10.1016/j.ymthe.2024.12.054. Epub 2024 Dec 30.
代谢编程与肿瘤微环境中的免疫抑制
Cancer Cell. 2023 Mar 13;41(3):421-433. doi: 10.1016/j.ccell.2023.01.009. Epub 2023 Feb 16.
4
Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.通过靶向清除M2样肿瘤相关巨噬细胞重塑肿瘤微环境用于癌症免疫治疗
Acta Biomater. 2023 Apr 1;160:239-251. doi: 10.1016/j.actbio.2023.02.006. Epub 2023 Feb 11.
5
Type I interferon/STAT1 signaling regulates UBE2M-mediated antiviral innate immunity in a negative feedback manner.I 型干扰素/STAT1 信号通路以负反馈方式调节 UBE2M 介导的抗病毒先天免疫。
Cell Rep. 2023 Jan 31;42(1):112002. doi: 10.1016/j.celrep.2023.112002. Epub 2023 Jan 19.
6
The emerging field of oncolytic virus-based cancer immunotherapy.溶瘤病毒为基础的癌症免疫疗法的新兴领域。
Trends Cancer. 2023 Feb;9(2):122-139. doi: 10.1016/j.trecan.2022.10.003. Epub 2022 Nov 17.
7
An armed oncolytic virus for GBM Destruction.一种用于破坏胶质母细胞瘤的武装溶瘤病毒。
Nat Cancer. 2022 Nov;3(11):1274-1276. doi: 10.1038/s43018-022-00457-z.
8
Macrophages in health and disease.巨噬细胞在健康与疾病中的作用
Cell. 2022 Nov 10;185(23):4259-4279. doi: 10.1016/j.cell.2022.10.007.
9
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity.通过先天免疫和适应性免疫,用表达西妥昔单抗-CCL5 融合蛋白的溶瘤病毒特异性靶向神经胶质瘤。
Nat Cancer. 2022 Nov;3(11):1318-1335. doi: 10.1038/s43018-022-00448-0. Epub 2022 Nov 10.
10
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.免疫病毒疗法:抗体药物与溶瘤病毒联合治疗的作用。
Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022.